1 / 15

Results

(1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters?. Alex-CIS-GCTOF MS w/ BinBase: 470 detected compounds 161 known metabolites, 309 without identified structure. grade2. grade1. Partial Least Square (multivariate stats).

berg
Download Presentation

Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF MS w/ BinBase: 470 detected compounds 161 known metabolites, 309 without identified structure. grade2 grade1 Partial Least Square (multivariate stats) Results grade3 grade1 grade3 breast adipose grade2

  2. Grade n1  23 tumors show differential up-regulation inPentose Phosphate Pathway, nucleotides, amino acids, arachidonic acid (but not free fatty acids, gln) Results production of NADPH, ribose units production of DNA, RNA

  3. Grade n1  23 tumors show differential up-regulation inPentose Phosphate Pathway, nucleotides, amino acids, arachidonic acid (but not free fatty acids, gln) Amino acids Amino acids citrate glu b-ala n 1 2 3 grade n 1 2 3 grade Results malate lactate n 1 2 3 grade n 1 2 3 grade C20:4 2HOglutarate IDH1? n 1 2 3 grade n 1 2 3 grade

  4. Can we validate biomarkers in a fully independent study?Cohort 2 (113 patients) Results

  5. Matej Orešič et al. (subm.) Can we validate lipidomic biomarkers in a fully independent study?Cohort 2 (113 patients) Results

  6. Orešič et al. (subm) Can we validate lipidomic biomarkers in a fully independent study? Immunohistochemistry on tissue slides. Results

  7. Can we get biochemical maps of differential regulation for hormone receptor status? Methods • Up to 20% of the identified metabolites lack enzyme annotations. • Metabolic endpoint metabolites accumulate more than intermediates. ‘Comprehensive maps’ do not work.

  8. Can we get biochemical maps of differential regulation for hormone receptor status? Methods • Up to 20% of the identified metabolites lack enzyme annotations. • Metabolic endpoint metabolites accumulate more than intermediates. ‘Comprehensive maps’ do not work.

  9. Chemical and biochemical mapping of metabolomic results Methods

  10. Grade 1 tumors vs normal Results Red nodes: up-regulated in tumors at p<0.05, size ~ x-fold Blue nodes: down-regulated in tumors at p<0.05, size~x-fold Red edges: enzyme substrate/product in KEGGRpair DB Green edges:chemical similarity > 0.7

  11. Hormone receptor @ grade 3 single neg. ER+ PR+ HER2- % of patients Methods triple neg. ER- PR- HER2- Estrogen positive Estrogen negative

  12. Metabolic phenotype of triple negative tumorsPatients without Estrogen, Herceptin neu2, Progesteron receptor Results

  13. Hormone receptor @ grade 3 % of patients Methods triple neg. ER- PR- HER2- double neg. ER- PR- HER2+ Estrogen positive Estrogen negative

  14. Effect of HER2 status on metabolic phenotype of triple negative tumors Results

  15. Hormone receptor @ grade 2 double pos. % of patients ER+ PR+ HER2- Methods triple pos. ER+ PR+ HER2+ Estrogen positive Estrogen negative

More Related